Key Segmentation:
By Application
-
Aortic Valve Stenosis
-
Pulmonary Valve Stenosis
-
Mitral Valve Stenosis
-
Others
By Product Type
-
Balloon Catheters
-
Cutting Balloon Devices
-
Inflation Devices
-
Accessories
By Balloon Type
-
Semi-Compliant
-
Non-Compliant
By End Use
-
Hospitals
-
Cardiac Catheterization Labs
-
Ambulatory Surgical Centers
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
Key players include Abbott Laboratories, Boston Scientific, Medtronic, B. Braun Melsungen, Edwards Lifesciences, Cordis, Teleflex, Becton Dickinson, Terumo, and Cook Medical, among others.
The development of high-pressure, precisely controlled balloon catheters and pediatric-specific valvuloplasty devices represent the two most significant opportunities shaping the market's next phase of growth.
Growth is primarily driven by the rising prevalence of valvular heart disease in an ageing population, combined with a strong preference for minimally invasive, catheter-based procedures.
By Application, Aortic Valve Stenosis dominated the market with a 58.40% share in 2025, reflecting the high prevalence of calcific aortic stenosis among older adults.
North America dominated the market with a 41.10% share in 2025, supported by a high prevalence of valvular disease, advanced healthcare infrastructure, and frequent product approvals, led by the United States.
